Company Profile: PhosphoGam

CED Life Science Conference 2018 - Lightning Round; Innovation Room

(website in development)
Sub-sector: Biotech and Pharmaceutical
Year Founded: 2015

COMPANY PROFILE
PhosphoGam is a pre-clinical cell therapy company focused on using gamma/delta T cells (γδ-T cells) obtained from healthy (allogeneic) donors to treat a variety of cancers. In contrast to conventional T cells, γδ-T cells can rapidly recognize and kill a wide variety of tumor cells, regardless of tissue of origin. This feature makes γδ-T cells ideal for use as an “off-the-shelf” cell therapy. Although γδ-T cells are extremely rare, PhosphoGam has developed the means to generate (manufacture) large numbers of γδ-T cells obtained from healthy donors for subsequent treatment for virtually any patient with any type of cancer. Moreover, in contrast to CAR-T cells (which can recognize only one pre-selected target), the “universal killer” γδ-T cells produced by PhosphoGam can be generated simply and reliably — without need of complex and costly genetic manipulations.

FOUNDERS/MANAGEMENT TEAM
Dr. Richard Lopez - CEO
Tim Gallagher - CBO

KEY MILESTONES TO DATE

  • Technical operations have commenced at BioLabs NC. Our next milestone is to produce sufficient data to win pharma and investor attention, in 1Q2018.

POWERED BY
Duke Office of Licensing and Ventures (OLV); LaunchBio

CONTACT
Tim Gallagher
tim@phosphogam.com
Durham, NC

Learn more about the CED Life Science Conference.